U.S. markets closed

  • S&P Futures

    4,222.00
    +12.00 (+0.29%)
     

  • Dow Futures

    33,360.00
    +100.00 (+0.30%)
     

  • Nasdaq Futures

    13,447.00
    +55.00 (+0.41%)
     

  • Russell 2000 Futures

    1,975.70
    +6.20 (+0.31%)
     

  • Crude Oil

    91.83
    -0.10 (-0.11%)
     

  • Gold

    1,801.60
    -12.10 (-0.67%)
     

  • Silver

    20.47
    -0.28 (-1.34%)
     

  • EUR/USD

    1.0286
    -0.0016 (-0.15%)
     

  • 10-Yr Bond

    2.7860
    -0.0110 (-0.39%)
     

  • Vix

    19.74
    -2.03 (-9.32%)
     

  • GBP/USD

    1.2184
    -0.0034 (-0.28%)
     

  • USD/JPY

    133.2900
    +0.4170 (+0.31%)
     

  • BTC-USD

    24,323.83
    +1,478.24 (+6.47%)
     

  • CMC Crypto 200

    573.44
    +42.22 (+7.95%)
     

  • FTSE 100

    7,507.11
    +18.96 (+0.25%)
     

  • Nikkei 225

    27,819.33
    -180.63 (-0.65%)
     

Delcath's Chemosat Hepatic Delivery System Shows Overall Response Rate Of 60.5% In Eye Cancer That Spreads To Liver

  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • DCTH

Delcath Systems Inc's (NASDAQ: DCTH) single-institution retrospective study data on CHEMOSAT Hepatic Delivery System for liver dominant metastatic uveal melanoma (mUM) were published in the journal Melanoma Research.

  • 41 of 81 (50.6%) patients had received other treatments, either systemic or liver-directed, before percutaneous hepatic perfusion (PHP) treatment. 250 PHP procedures were performed in 81 patients.

  • The Company's PHP system is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

  • The PHP system is being developed under the tradename, Hepzato Kit.

  • Related: Delcath Systems Reveals Initial Survival Data From Ocular Melanoma Trial.

  • The analysis demonstrated a hepatic disease control rate of 88.9% (72/81), a hepatic response rate of 66.7%, and an overall response rate of 60.5%.

  • After a median follow-up of 12.9 months, median overall progression-free survival (PFS) and median overall survival (OS) were 8.4 and 14.9 months, respectively.

  • Treatment-emergent adverse events of Grade 3 or 4 occurred in 23 patients, anemia observed in 11 patients (13.3%), and thrombocytopenia in 10 patients (12%).

  • There were no fatal treatment-related adverse events.

  • Price Action: DCTH shares closed at $6.99 on Thursday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Recommended Stories

  • ‘Load Up,’ Says Jim Cramer About These 2 ‘Strong Buy’ Stocks

    The last few years saw the markets go crazy. Between the COVID lockdowns and market crash, the rebound recovery, last year’s sustained bull run, and this year’s devastating first half that saw the bull turn into a bear. But in all of that, there have been stocks that have outperformed the market. These winning stocks have attracted attention from Jim Cramer, the well-known host of CNBC’s ‘Mad Money’ program. Among other things, Cramer has been following stocks which won big during the COVID cris

  • Disney stock pops amid earnings beat and streaming subscriber growth

    Yahoo Finance reporter Allie Canal breaks down Disney's latest earnings results and how it's moving shares to the upside.

  • NIO: Mounting Headwinds Batter Investor Confidence

    Persistent supply issues have deflated expectations for the Chinese automaker

  • Coupang, Inc. (CPNG) Reports Q2 Loss, Misses Revenue Estimates

    Coupang, Inc. (CPNG) delivered earnings and revenue surprises of 63.64% and 2.24%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

  • Oregon biotech Siga Technologies set to deliver first monkeypox treatment

    Four years after Siga Technologies (Nasdaq: SIGA) gained approval for a smallpox drug, the Corvallis company is gearing up to get the same antiviral into a clinical trial for monkeypox. Tpoxx, also known as tecovirimat, is the only drug available to treat the virus, though it is not yet approved in the U.S. for the disease. The Food and Drug Administration designated Tpoxx as an investigational drug for monkeypox, allowing it to be released from the Strategic National Stockpile only after prescribers jump through considerable hoops.

  • US Politicians are Selling These 10 Stocks

    In this article, we discuss the 10 stocks that US Politicians are selling. If you want to read about some more stocks that US Politicians are selling, go directly to US Politicians are Selling These 5 Stocks. Recession fears in the United States stock market have been gathering pace for the past few weeks, even […]

  • Should I sell my house now before prices crash — or wait for the next big real estate boom?

    The housing market is changing fast. Act accordingly.

  • Rivian set to report second-quarter earnings after hours on Thursday

    Yahoo Finance Live co-host Rachelle Akuffo looks at Rivian's stock ahead of its earnings report due out tomorrow.

  • Down More Than 40%: These 2 ‘Strong Buy’ Stocks Are Flirting With a Bottom

    While every market advisor will tell you never to try to ‘time’ the market, timing is still important for success. Investors need to buy into low prices, and to do that, they need to know when prices are low. This doesn’t necessarily mean low in absolute dollar terms, but low relative to a stock’s recent past performance. In recognizing that lower price range, investors can turn to Wall Street’s pros for help. The analysts have been busy lately, picking out stocks that are in their lower price r

  • Are you still paying 1% to your financial adviser? Here’s what might make a lot more sense — and save you tens of thousands of dollars

    Many financial advisers charge based on how much money they manage on your behalf, and 1% of your total assets under management is a pretty standard fee. “Under $1 million dollars of investable assets, the flat fee may consume a very large percentage of their account and that would not be smart or advisable for the client,” says Paddock. In general, clients would do well to understand that percentage fees work well on smaller balances while flat fees are best for larger asset balances — and using the $1 million dollar threshold can be an easy way to draw a line in the sand for a client, says Kaleb Paddock, certified financial planner at Ten Talents Financial Planning.

  • Mocked by Everyone, Stock Rally Sits at Cusp of a Chart Landmark

    (Bloomberg) -- It’s doomed, it’s a bear-market rally, a rebound that won’t last. All the mud thrown at equities over the last month may well turn out to be true. But it’s getting harder to brush aside the recovery in the S&P 500 as it hovers at a widely watched landmark in charts.Most Read from BloombergMusk Sells Another $6.9 Billion of Tesla Ahead of Twitter TrialUS Inflation Runs Cooler Than Forecast, Easing Pressure on FedDozens in China Infected With New ‘Langya’ Virus Carried by ShrewsRuss

  • You'll Be Sorry If You Sell These 7 Value Stocks Now, Analysts Say

    Value stocks in the S&P 500 are outperforming this year. But analysts still think it's a mistake to part with some of them too soon.

  • What Awaits ZIM Integrated Shipping (ZIM) in Q2 Earnings?

    High fuel costs might have hurt the Q2 bottom-line performance of ZIM Integrated Shipping (ZIM).

  • This Analyst is Bullish on 8 Auto Stocks for the Rest of 2022

    In this article, we’ll discuss the 8 auto stocks analyst Itay Michaeli at Citi has a bullish stance on. If you want to skip our discussion on the automotive industry outlook, go directly to This Analyst is Bullish on 4 Auto Stocks for the Rest of 2022. In a research note issued on August 2, […]

  • Four REITS That Pay Monthly Dividends

    One of the big advantages of owning certain real estate investment trusts (REITs) over common stock is this: Some pay dividends monthly. Stocks pay dividends quarterly, which is nice, but monthly sounds better to more than a few investors. With that in mind, here are five REITs paying the monthly dividends. 1. Agree Realty Corp. (NYSE: ADC) pays a 3.61% annualized dividend and trades on the New York Stock Exchange with an average daily volume of 815,000 shares. The monthly dividend payment is $0

  • Why Vuzix Stock Skyrocketed Today

    Shares of Vuzix (NASDAQ: VUZI), a smart-glasses and augmented reality company, soared today after the company reported its second-quarter financial results. While the company's bottom line missed Wall Street's expectations, Vuzix's revenue outpaced analysts' consensus estimate in the quarter. Vuzix reported a second-quarter non-GAAP (adjusted) loss of $0.16 per share, down from a loss of $0.15 in the year-ago quarter and missing Wall Street's average estimate of a loss of $0.15.

  • Lithium Likely to Become a De-Facto Precious Metal: 5 Picks

    We have narrowed our search to five lithium producers. These are: ALB, LTHM, PLL, LAC and SQM.

  • FCC denies SpaceX's Starlink its $1 billion bid on rural broadband expansion

    Yahoo Finance Live's Rachelle Akuffo reports on the FCC rebuffing SpaceX's bid for rural broadband subsidies.

  • United Parcel Service, Inc. (NYSE:UPS) Passed Our Checks, And It's About To Pay A US$1.52 Dividend

    United Parcel Service, Inc. ( NYSE:UPS ) stock is about to trade ex-dividend in day or two. The ex-dividend date is one...

  • This is the ‘Jay Leno rule’ of saving money — and you don’t have to be rich to make it work for you

    Comedian Jay Leno has openly shared that while collecting two salaries — one from his Tonight Show hosting gig and one from the 150 annual comedy shows he’d appear in — he never spent any of his Tonight Show salary and instead only spent what he made doing stand-up. Certified financial planner Don Grant advises reviewing your spending and netting it against your income.